Shand J H, West D W
Hannah Research Institute, Ayr, UK.
Biochim Biophys Acta. 1995 Mar 16;1255(2):123-30. doi: 10.1016/0005-2760(94)00227-p.
Male rats were fed for 10 days on a diet supplemented with either probucol or clofibrate, alone or in combination, and the effects of the drugs on hepatic cholesterol metabolism studied. Plasma triacylglycerols were significantly lowered (15.6%, P < 0.05) by the drugs in combination but not individually whereas plasma cholesterol levels were reduced by probucol alone (22.4%, P < 0.05) and the combined treatment effected a further decrease leading to a total reduction of 50.6% (P < 0.001). Probucol reduced hepatic cellular triacylglycerols (20.0%, P < 0.05) and cholesterol (15.3%, P < 0.05) but cholesteryl esters were unaffected. In combination with clofibrate, probucol accentuated the reductions in both cellular cholesterol and cholesteryl esters produced by clofibrate alone and lowered their levels by 22.8%, P < 0.01 and 38.5%, P < 0.001, respectively. Although probucol, on its own, did not affect the activity of acyl-coenzyme A:cholesterol acyltransferase (ACAT), its combination with clofibrate caused less inhibition (43.5%, P < 0.01) of this enzyme activity than clofibrate alone (65.7%, P < 0.001). Probucol had a similarly moderating effect on the clofibrate-induced reductions in microsomal cholesterol and cholesteryl esters. Neither the microsomal nor the cytosolic neutral cholesteryl ester hydrolase was affected by probucol alone although both enzymes were dramatically increased (between 350% and 550%) by clofibrate and the combined treatment. The activity of the hepatic cytosolic inhibitor of cholesteryl ester hydrolase was unaffected by clofibrate or probucol individually but the two drugs in combination increased the total activity of the inhibitor by 52.1%, P < 0.01. When allowance was made for this increased inhibitor activity, it was clear that probucol accentuated the stimulatory effect of clofibrate on the cytosolic nCEH.
雄性大鼠分别用普罗布考或氯贝丁酯单独或联合添加到饮食中喂养10天,并研究药物对肝脏胆固醇代谢的影响。联合用药可显著降低血浆甘油三酯水平(15.6%,P<0.05),但单独用药则无此效果,而单独使用普罗布考可降低血浆胆固醇水平(22.4%,P<0.05),联合治疗可进一步降低,导致总降低率达50.6%(P<0.001)。普罗布考可降低肝细胞甘油三酯(20.0%,P<0.05)和胆固醇(15.3%,P<0.05),但胆固醇酯不受影响。与氯贝丁酯联合使用时,普罗布考可增强氯贝丁酯单独产生的细胞胆固醇和胆固醇酯的降低作用,使其水平分别降低22.8%,P<0.01和38.5%,P<0.001。虽然普罗布考单独使用不影响酰基辅酶A:胆固醇酰基转移酶(ACAT)的活性,但其与氯贝丁酯联合使用对该酶活性的抑制作用(43.5%,P<0.01)小于氯贝丁酯单独使用(65.7%,P<0.001)。普罗布考对氯贝丁酯诱导的微粒体胆固醇和胆固醇酯的降低也有类似的调节作用。单独使用普罗布考对微粒体和胞质中性胆固醇酯水解酶均无影响,尽管氯贝丁酯和联合治疗均可使这两种酶显著增加(350%至550%)。氯贝丁酯或普罗布考单独使用时,肝胞质胆固醇酯水解酶抑制剂的活性不受影响,但两种药物联合使用可使抑制剂的总活性增加52.1%,P<0.01。考虑到这种增加的抑制剂活性后,很明显普罗布考增强了氯贝丁酯对胞质nCEH的刺激作用。